ClinicalTrials.gov recorded primary completion on 2026-07-06 for NCT05261399, a phase 3 study of osimertinib in non-small-cell lung cancer. The trial compared savolitinib plus osimertinib with platinum-based doublet chemotherapy in 341 participants who had progressed on osimertinib treatment.
Background
The study focused on participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic non-small-cell lung cancer. According to the posted record, the trial evaluated whether adding savolitinib to Tagrisso could offer benefit after progression on osimertinib.
Trial design
The ClinicalTrials.gov record describes an ACTIVE_NOT_RECRUITING randomized study with 341 enrolled participants. The intervention arms included savolitinib plus osimertinib versus platinum-based doublet chemotherapy, with pemetrexed, cisplatin, and carboplatin listed among the study treatments.
What this means
Primary completion means the trial finished collecting data for its main outcome measures, but the posted record does not include results in this event notice. For clinicians and researchers, the study remains important because it tests a targeted combination against chemotherapy in a population with progression on osimertinib, a setting where post-progression treatment options are clinically relevant.
Source
This information is based on ClinicalTrials.gov trial record NCT05261399 with primary completion dated 2026-07-06. The record is available at clinicaltrials.gov.